Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a chronic, recurrent lymphoproliferative disorder of the skin that belongs to the group of primary cutaneous CD30-positive T-cell lymphomas.
|
11168749 |
2001 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is defined as a recurrent self-healing papulonodular eruption with the histological features of a (CD30+) cutaneous T-cell lymphoma.
|
11531801 |
2001 |
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a recurrent, self-healing eruption belonging to the spectrum of cutaneous CD30+lymphoproliferative disorders.
|
20661014 |
2010 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is defined as a chronic recurrent skin disease characterized by waxing and waning papules and nodules with histologic features of a CD30-positive T-cell lymphoma.
|
22688398 |
2012 |
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) type E is a recently delineated variant characterized by the occurrence of large necrotic "eschar"-like lesions displaying microscopically angioinvasive and angiodestructive infiltrates composed of CD30 lymphocytes, frequently coexpressing CD8.
|
28937425 |
2018 |
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lymphomatoid papulosis type E (LyP) is a recently described subtype of LyP characterized by an angioinvasive infiltrate of atypical lymphocytes expressing CD30.
|
29067932 |
2018 |
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) type E is a recently described variant characterized by the occurrence of large necrotic eschar-like lesions displaying microscopically angioinvasive and angiodestructive infiltrates of CD30+ lymphocytes, frequently coexpressing CD8.
|
30957244 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a benign chronic often relapsing skin condition that belongs to the CD30-positive cutaneous lymphoproliferative disorders.
|
31494989 |
2020 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis and cutaneous CD30+ lymphoma.
|
8806956 |
1996 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30-positive primary cutaneous lymphoproliferative disorders include several entities with differing clinical presentation but overlapping histological features, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (C-ALCL).
|
25131361 |
2015 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL.
|
31705818 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A skin biopsy revealed a dermal infiltrate of CD4, CD8 and CD30-positive T-cells, consistent with lymphomatoid papulosis.
|
23713913 |
2014 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the papular clinical appearance, lymphocyte atypia, and focal CD30 positivity may resemble LyP, the relatively low number of atypical lymphocytes, low intensity of CD30 staining, and absence of spontaneous resolution help to distinguish PPPD from LyP.
|
31188140 |
2020 |
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Another photoresponsive CTCL variant is lymphomatoid papulosis (LP), a CD30+ lymphoproliferative disease characterised by chronically recurring papules.
|
30325389 |
2018 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, brentuximab vedotin, an antibody-drug conjugate composed of an anti-cluster of differentiation (CD)-30 antibody covalently linked to monomethyl auristatin E, is approved for the treatment of CD30+ lymphoproliferative disorders [lymphomatoid papulosis (LyP) and primary cutaneous-anaplastic large-cell lymphoma (pc-ALCL)] as well as transformed CD30+ mycosis fungoides (MF).
|
30430444 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BIA-ALCL resembles CD30+ cutaneous LPD: ALK-, CD30+ anaplastic cells with an aberrant T cell phenotype; overexpression of oncogenes (JUNB, SATB1, pSTAT3, SOCS3) in lymphomatoid papulosis (LyP); frequent apoptosis; complete spontaneous regression in LyP and partial spontaneous regression in cutaneous ALCL.
|
31577659 |
2020 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.
|
30520526 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous CD30+ lymphoproliferative disorders constitute many cutaneous T-cell lymphomas and comprise lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL).Both have an excellent prognosis.
|
31466587 |
2019 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four of these patients subsequently developed MF; (3) Lymphomatoid papulosis (waxing and waning lesions and positivity for CD30) (n=10; M:F=4:6; median age, 41 y; range, 16 to 83 y); (4) MF (clinical features typical of MF) (n=11; M:F=6:5; median age, 17 y; range, 8 to 85 y).
|
29851705 |
2018 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical stains for CD8, CD30, CD79 and CLA may be valuable tools in the differential diagnosis between PLEVA and LyP.
|
11553311 |
2001 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In situ hybridization studies showed positivity of the neoplastic cells for EBER in two of 16 cases of CD30+ ALCL and in none of the cases of LyP.
|
17076712 |
2006 |
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we determined that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, are associated with the development of lymphomatoid papulosis and CD30+ lymphomas in lymphomatoid papulosis patients, respectively.
|
15894695 |
2005 |